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Abstract  355 
Elevated serum urate levels cause gout, and correlate with cardio-metabolic diseases via poorly 356 
understood mechanisms. We performed a trans-ethnic genome-wide association study of 357 
serum urate among 457,690 individuals, identifying 183 loci (147 novel) that improve prediction 358 
of gout in an independent cohort of 334,880 individuals. Serum urate showed significant 359 
genetic correlations with many cardio-metabolic traits, with genetic causality analyses 360 
supporting a substantial role for pleiotropy. Enrichment analysis, fine-mapping of urate-361 
associated loci and co-localization with gene expression in 47 tissues implicated kidney and liver 362 
as main target organs and prioritized potentially causal genes and variants, including the 363 
transcriptional master regulators in liver and kidney, HNF1A and HNF4A. Experimental 364 
validation showed that HNF4A trans-activated the promoter of the major urate transporter 365 
ABCG2 in kidney cells, and that HNF4A p.Thr139Ile is a functional variant. Transcriptional co-366 
regulation within and across organs may be a general mechanism underlying the observed 367 
pleiotropy between urate and cardio-metabolic traits. 368 
 369 
 370 
 371 
  372 
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Introduction  373 
 374 
Serum urate levels reflect a balance between uric acid production and its net excretion via 375 
kidney and intestine. Elevated serum urate levels define hyperuricemia, which is associated 376 
with components of the metabolic syndrome as well as with cardiovascular and kidney disease. 377 
Hyperuricemia can cause kidney stones and gout, the most common form of inflammatory 378 
arthritis1,2. Gout attacks are a highly painful inflammatory response to the deposition of urate 379 
crystals, and are a significant cause of morbidity, emergency room visits and related health care 380 
costs3. Although gout has become a major public health issue, it is undertreated due to low 381 
awareness, poor patient adherence4 and inappropriate prescription practices of the most 382 
commonly used drug, allopurinol5. A better understanding of the mechanisms controlling serum 383 
urate levels may not only help to develop novel medications to treat and prevent gout, but also 384 
provide insights into regulatory mechanisms shared with urate-associated cardio-metabolic risk 385 
factors and diseases.  386 
Genetic heritability of serum urate varies between 30% and 60% in diverse populations6-387 
11. Candidate gene and early genome-wide associations studies (GWAS) have identified three 388 
genes as major determinants of urate levels: SLC2A9, ABCG2, and SLC22A127,12-18. While SLC2A9 389 
and ABCG2 harbor common variants of relatively large effect19, SLC22A12 contains many rare or 390 
low-frequency variants associated with lower serum urate levels20. The largest GWAS meta-391 
analyses performed to date identified 28 associated genomic loci among European ancestry 392 
(EA) individuals21 and 27 among Japanese individuals22. Many genes in the associated loci 393 
encode urate transporters or their regulators in kidney and gut, while others are relevant to 394 
glucose and lipid metabolism, central functions of the liver, where uric acid is generated. Earlier 395 
GWAS did not perform fine-mapping coupled to functional annotation or co-localization with 396 
gene expression across tissues to prioritize target tissues, pathways, and potentially causal 397 
genes and variants. These approaches have only recently become available owing to increased 398 
public availability of large datasets23,24. 399 
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Here, we perform a trans-ethnic GWAS meta-analysis of serum urate among 457,690 400 
individuals and identify 183 associated genetic loci that improve risk prediction of gout in an 401 
independent sample of 334,880 individuals from the UK Biobank. We evaluate the genetic 402 
correlation of serum urate with hundreds of cardio-metabolic traits and diseases, and use a 403 
recently developed latent causal variable model to examine the contribution of causality versus 404 
pleiotropy. We prioritize target variants, genes, tissues and pathways that contribute to the 405 
complex regulation of urate levels through comprehensive data integration. To validate the 406 
prioritization workflow, we conduct proof-of-principle experimental studies showing that 407 
HNF4A, a transcriptional master regulator in liver and kidney proximal tubule, can regulate 408 
transcription of the major urate transporter ABCG2 in kidney cells and that the fine-mapped 409 
HNF4A variant p.Thr139Ile is functional. Transcriptional co-regulation of processes linked to 410 
energy metabolism within and across organs may underlie the pleiotropy we uncovered 411 
between urate levels and numerous cardio-metabolic traits.  412 
 413 
Results 414 
Meta-analyses and characterization of serum urate-associated loci  415 
Overview 416 
Trans-ethnic meta-analyses were conducted to maximize the sample size for studying the 417 
genetic landscape of serum urate. EA-specific analyses were used where population-specific 418 
linkage disequilibrium (LD) was required for prioritizing urate-associated genes, tissues, and 419 
pathways, identifying genetic correlations with other traits, and to perform gout risk prediction 420 
(Supplementary Figure 1). 421 
Trans-ethnic meta-analysis identifies 183 loci associated with serum urate  422 
The primary trans-ethnic GWAS meta-analysis included 457,690 individuals (EA, n=288,649; 423 
East Asian ancestry [EAS], n=125,725; African Americans [AA], n=33,671; South Asian ancestry 424 
[SA], n=9,037; and Hispanics [HIS], n=608) from 74 studies, with mean urate levels ranging from 425 
4.2 to 7.2 mg/dl (Supplementary Table 1). GWAS were performed based on genotypes imputed 426 
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using the 1000 Genomes Project or Haplotype Reference Consortium reference panels 427 
(Methods, Supplementary Table 2). Following standardized study-specific quality control and 428 
variant filtering procedures, we combined results through inverse-variance weighted fixed 429 
effect meta-analysis. There was no evidence of inflation due to unmodeled population 430 
structure (LD score regression intercept=1.01; genomic inflation factor λGC=1.04). Post-meta-431 
analysis variant filtering left 8,249,849 high-quality SNPs for downstream analyses (Methods).  432 
We identified 183 loci, defined as the +/-500 kb region around the SNP with the lowest 433 
p-value (index SNP), that contained at least one SNP associated at genome-wide significance 434 
(p≤5x10-8, Figure 1, Supplementary Table 3). Of these, 36 contained a SNP reported as the 435 
index SNP in previous GWAS of serum urate13,15,17,18,21,22,25,26, and 147 were considered novel 436 
(Figure 1). Absolute effect estimates of each copy of the respective index SNP on serum urate 437 
ranged from 0.28 mg/dl (known SLC2A9 locus) to 0.017 mg/dl (novel KLB locus). The average 438 
absolute effect across all index SNPs was of 0.038 mg/dl (standard deviation [SD] 0.033). 439 
Regional association plots for all 183 loci are shown in Supplementary Figure 2.  440 
The index SNPs at all 183 loci explained an estimated 7.7% of the serum urate variance 441 
(Methods), as compared to 5.3% of the variance explained by variants previously reported by 442 
GWAS in EA populations21. In a large participating general population-based pedigree study, the 443 
183 index SNPs explained 17% of serum urate genetic heritability (h2=37%, 95% credible 444 
interval: 29%, 45%). The index SNPs at the three major urate loci SLC2A9, ABCG2 and SLC22A12 445 
explained 5% of the genetic heritability (Supplementary Figure 3; Methods). 446 
Characterization of ancestry-related heterogeneity  447 
For the 183 index SNPs, we observed no evidence of systematic between-study heterogeneity 448 
(median I2=2%, interquartile range 0-14%; Supplementary Table 3). Fourteen index SNPs 449 
showed significant evidence of ancestry-associated heterogeneity (panc-het<2.7x10-4=0.05/183) 450 
when tested using meta-regression (Supplementary Figure 4, Methods), consistent with their 451 
higher measures of between-study heterogeneity (I2>25%, Figure 1, Supplementary Table 3). 452 
The most significant ancestry-associated heterogeneity was observed for the index SNP 453 
rs3775947 at SLC2A9 (panc-het=1.5x10-127, effect per copy of the coded allele in EA 0.34 mg/dl, AA 454 
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0.26 mg/dl, EAS 0.17 mg/dl, HIS 0.41 mg/dl, and SA 0.21 mg/dl), consistent with previous 455 
reports of population heterogeneity of genetic effects at this locus27. In addition, nine genome-456 
wide significant loci were identified through meta-regression that did not overlap with the 183 457 
significant loci from the primary trans-ethnic fixed-effects meta-analysis. Of these, the index 458 
SNPs at SLC2A2 and KCNQ1 were genome-wide significant in EAS (Supplementary Table 4). 459 
Results from ancestry-specific meta-analyses of EA, AA, EAS and SA are summarized in 460 
Supplementary Tables 5 to 8, respectively, as well as in the Supplementary Information.  461 
Sex-stratified meta-analyses of serum urate GWAS  462 
Mean serum urate levels and gout risk are higher in men than in women28. We therefore 463 
performed secondary sex-specific analyses to evaluate whether the 183 urate-associated index 464 
SNPs showed sex-specific differences. After multiple-testing correction, six SNPs showed 465 
significant effect differences (Pdiff<2.7x10-4=0.05/183), at SLC2A9, ABCG2, CAPN1, GCKR, IDH2, 466 
and SLC22A12 (Supplementary Table 9). A genome-wide test for differences in genetic effects 467 
on urate levels between men and women identified only SNPs at SLC2A9 and ABCG2 as 468 
significant (pdiff<5x10-8, Methods, Supplementary Figure 5), consistent with previous 469 
reports,7,14,15,21 with few additional loci outside of the extended sex-specific regions that were 470 
suggestive of sex differences (pdiff<1x10-5, Supplementary Table 10).  471 
 472 
Epidemiological and clinical landscape 473 
Urate-associated SNPs are associated with gout  474 
To assess the association of the 183 trans-ethnic urate index SNPs with gout, we investigated 475 
their effects in a trans-ethnic meta-analysis of gout from 20 studies, based on 763,813 476 
participants including 13,179 with gout (Methods, Figure 1, Supplementary Table 1). Consistent 477 
with the causal role of hyperuricemia in gout, genetic effects were highly correlated (Spearman 478 
correlation coefficient 0.87, Supplementary Figure 6A); 55 SNPs were significantly associated 479 
with gout (p<2.7x10-4=0.05/183). In agreement with previous findings29, the largest odds ratio 480 
(OR) for gout was observed at ABCG2 (rs74904971, OR 2.04, 95% confidence interval [CI] 1.96-481 
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2.12, P=7.7x10-299). The genetic effects were generally higher among index SNPs with lower 482 
minor allele frequency (MAF), with the exception of a few large-effect SNPs with MAF>10%, 483 
mapping into loci that encode urate transporters with known major effects on urate levels: 484 
SLC2A9, ABCG2, and SLC22A1230 (Supplementary Figure 6B). 485 
 486 
A genetic risk score for urate improves risk prediction for gout  487 
We evaluated whether a weighted urate genetic risk score (GRS) improved risk prediction of 488 
gout when added to demographic information in a large, independent sample of 334,880 489 
individuals from the UK Biobank (UKBB), including 4,908 gout cases (Methods). Across 490 
categories of the urate GRS, gout prevalence increased from 0.1% in the lowest GRS category to 491 
12.9% in the highest GRS category (Figure 2A, Supplementary Table 11). Using the most 492 
common GRS category as the reference, the age- and sex-adjusted OR of gout ranged from 0.09 493 
(95% CI 0.02-0.37, p=7.8x10-4) in the lowest GRS category to 13.6 (95% CI 7.2-25.7, p=1.4x10-15) 494 
in the highest GRS category (Figure 2B, Supplementary Table 11). Of note, the 3.5% of 495 
individuals in the three highest GRS categories had a >3-fold increase in the risk of gout 496 
compared to individuals in the most common GRS category. This risk is comparable to a 497 
monogenic disease of modest effect size31, but affects a comparatively higher proportion of the 498 
population.  499 
We additionally constructed gout risk prediction models in the independent UK Biobank 500 
sample by regressing gout status on the GRS alone (“genetic model”), on age and sex 501 
(“demographic model”), and on the GRS, age, and sex (“combined model”) in a random training 502 
subset consisting of 90% of the individuals. These models were then used to predict gout status 503 
in the remaining 10%. The genetic model (area under the receiver operating characteristic 504 
curve [AUC]=0.68) was a weaker predictor than the demographic model (AUC=0.79), but 505 
addition of the GRS to the demographic model (combined model) significantly increased the 506 
prediction accuracy (AUC=0.84, DeLong’s test p<2.2x10-16; Figure 2C). The combined model 507 
achieved a sensitivity of 84% and specificity of 68% (Methods). The GRS represents a life-long 508 
predisposition to higher urate levels and can be calculated at birth without measurement of 509 
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serum urate. As opposed to synovial fluid analysis or CT-based imaging to diagnose gout, the 510 
GRS is less invasive and avoids radiation exposure, Thus, the GRS may have utility to identify 511 
individuals with a high genetic predisposition for gout, allowing for compensatory lifestyle 512 
choices to be made earlier in life to reduce the risk of developing gout.  513 
 514 
High genetic correlations of serum urate with cardio-metabolic traits  515 
Serum urate is positively correlated with many cardio-metabolic risk factors and diseases32. We 516 
assessed genetic correlations between serum urate and 748 complex traits using cross-trait LD 517 
score regression (Methods). Serum urate levels were significantly (p<6.6x10-5=0.05/748) 518 
genetically correlated with 214 complex traits and diseases (Supplementary Table 12). The 519 
highest positive genetic correlation (rg) was with gout (rg=0.92, p=3.3x10-70), followed by traits 520 
representing components of the metabolic syndrome such as HOMA-IR (rg=0.49) and fasting 521 
insulin (rg=0.45). Significant positive genetic correlations were also observed for other cardio-522 
metabolic traits or diseases, including waist circumference, obesity, and type 2 diabetes (Figure 523 
3). The largest negative correlations were observed with HDL cholesterol-related 524 
measurements (rg up to -0.46), and with estimated glomerular filtration rate (rg=-0.38 and -0.26 525 
for cystatin C-based and creatinine-based eGFR, respectively), consistent with the known role 526 
of the kidneys in urate excretion. Overall, the genetic correlations between serum urate and 527 
other complex traits and diseases were consistent with observational associations of serum 528 
urate levels with cardio-metabolic traits in epidemiological studies32. 529 
 To examine whether these genetic correlations reflect causal relationships or pleiotropy, 530 
we applied a recently-developed latent causal variable model to estimate the genetic causality 531 
proportion (GCP) for seven commonly-studied cardio-metabolic traits (Methods). As a positive 532 
control, we analyzed gout, confirming a genetically causal effect of urate on gout (GCP=0.79, 533 
Supplementary Table 13). Conversely, we identified a range of GCP values consistent with 534 
mostly or partially genetically causal effects of the seven cardio-metabolic traits on serum urate 535 
levels. The highest GCP estimates were observed for adiposity-related traits (e.g. GCP=0.84 for 536 
waist circumference, Supplementary Table 13), consistent with higher cell numbers resulting in 537 
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higher production of purines and consequently urate, as well as with a Mendelian 538 
Randomization study that reported a causal effect of adiposity on urate levels.33 HDL 539 
cholesterol levels, on the other hand, showed smaller GCP estimates (GCP<0.5; Supplementary 540 
Table 13), suggesting the existence of a genetic process with a causal effect on both HDL 541 
cholesterol and urate. A potential explanation for such a process are co-regulated metabolic 542 
processes in the liver that influence both cholesterol and urate levels. These processes may 543 
explain a large fraction of heritability for cholesterol levels and a modest fraction of heritability 544 
for urate, a type of asymmetry expected to produce a partially genetically causal relationship 545 
consistent with the one observed. 546 
Identification of enriched tissues and pathways  547 
To identify molecular mechanisms and tissues relevant for urate metabolism and handling, and 548 
to provide potential clues to the observed genetic correlation with other traits and diseases, we 549 
investigated which tissues, cell types and systems may be significantly enriched for the 550 
expression of genes mapping into the urate-associated loci. Based on all SNPs with P<1x10-5 551 
(Methods), we identified significant enrichment (false discovery rate [FDR] <0.01) for 19 552 
physiological system entries, three tissues, and two cell types (Supplementary Table 14). The 553 
strongest enrichment was observed for kidney (P=9.5x10-9) and urinary tract (P=9.9x10-9), both 554 
within the urogenital system, consistent with the kidney’s prominent role in controlling serum 555 
urate concentrations. Additional significant enrichments were observed in the endocrine and 556 
digestive system, including liver, the major site of urate production. Interestingly, a novel 557 
significant enrichment was also observed in the musculoskeletal system, specifically for synovial 558 
membrane, joint capsule, and joints (Figure 4A), the sites of gout attacks.  559 
We next tested for cell-type groups with evidence for enriched heritability based on cell-560 
type specific functional genomic elements using stratified LD score regression (Methods). The 561 
strongest heritability enrichment was observed for kidney (11.5-fold), followed by liver (5.39-562 
fold; Supplementary Table 15). This approach complemented the gene expression-based 563 
approach and also supported kidney and liver as the major organs of urate homeostasis.  564 
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Lastly, we tested whether any gene sets were enriched for variants associated with 565 
urate at P<10-5 (Methods). Significant enrichment (FDR <0.01) was observed for 383 566 
reconstituted gene sets (Supplementary Table 16). Since many of these contained overlapping 567 
groups of genes, we used affinity propagation clustering to identify 57 meta gene sets 568 
(Methods, Supplementary Table 17), including a prominent group of inter-correlated gene sets 569 
related to kidney and liver development, morphology and function (Figure 4B). Together, these 570 
analyses underscore the prominent role of the kidney and liver in regulating serum urate levels 571 
and implicate the kidney as a major target organ for lowering of serum urate levels. 572 
 573 
Prioritization of urate loci based on statistical fine-mapping, functional annotation, and gene 574 
expression 575 
To prioritize target SNPs and genes for translational research, we established a workflow that 576 
combined fine-mapping of urate-associated loci with functional annotation and a systematic 577 
evaluation of tissue-specific differential gene expression. 578 
Statistical fine-mapping prioritizes candidate SNPs 579 
To identify independent and potentially causal variants, statistical fine-mapping was performed 580 
starting from the 123 genome-wide significant loci identified in the EA-specific meta-analysis, 581 
because the workflow included methods that used LD estimates from an ancestry-matched 582 
reference panel (Methods)34. After combining the 123 loci into 99 larger genomic regions based 583 
on LD between index SNPs, stepwise model selection in each region identified 114 independent 584 
SNPs (r2<0.01, Methods). Overall, 87 regions contained one independent signal, ten contained 585 
two independent SNPs, the ABCG2 locus contained three and the SLC2A9 locus four 586 
independent SNPs (Supplementary Table 18). For each of these 114 independent SNPs, we 587 
computed 99% credible sets representing the smallest set of SNPs which collectively account 588 
for 99% posterior probability of containing the variant(s) driving the association signal35. The 589 
99% credible sets contained a median of 16 SNPs (Q1, Q3: 6, 57), and six of them only a single 590 
SNP, mapping in or near INSR, RBM8A, MPPED2, HNF4A, CPT1C, and SLC2A9 (Supplementary 591 
Table 18). Among 28 small credible sets (≤5 SNPs), several mapped in or near genes with an 592 
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established role in regulating urate levels such as SLC2A9, PDZK1, ABCG2, SLC22A11, and 593 
SLC16A920. These credible sets contain the most supported candidate SNPs based on the serum 594 
urate association signals and would greatly reduce the number of candidate functional variants 595 
to be tested in experimental follow-up studies.  596 
To further refine the credible set SNPs, we annotated them with respect to their 597 
functional consequence and regulatory potential (Methods). Missense SNPs with posterior 598 
probabilities >50% for driving the association signals or mapping into small credible sets were 599 
identified in ABCG2, UNC5CL, HNF1A, HNF4A, CPS1, and GCKR (Supplementary Table 19, Figure 600 
5A). All missense SNPs except the one in GCKR had a CADD score >15, supporting the SNP and 601 
the gene it resides in as potentially causal. Indeed, functional effects have already been 602 
demonstrated experimentally for variants rs2231142 (Gln141Lys, r2=1 to the index SNP 603 
rs74904971) in ABCG2, rs742493 (p.Arg432Gly) in UNC5CL, and rs1260326 (p.Leu446Pro) in 604 
GCKR (Table 1). Non-exonic variants with posterior probabilities of >90% and mapping into 605 
open chromatin in enriched tissues were identified in RBM8A, SLC2A9, INSR, HNF4A, PDZK1, 606 
NRG4, UNC5CL, and AAK1 (Methods, Supplementary Figure 7, Supplementary Table 19). When 607 
complemented by evidence of gene expression co-localization, these SNPs may represent 608 
causal regulatory variants and highlight their potential effector genes.  609 
Gene prioritization via gene expression co-localization analyses 610 
To systematically assess differential gene expression, we tested for co-localization of the urate 611 
association signals with expression quantitative trait loci (eQTL) in cis across three kidney tissue 612 
resources and 44 GTEx tissues (Methods). High posterior probability of co-localization (H4≥0.8, 613 
Methods) supports a trait-associated variant acting through modulation of gene expression in 614 
the tissue where co-localization is identified. The eQTLs from the three kidney tissue resources 615 
were based on glomerular and tubulo-interstitial portions of micro-dissected kidney biopsies 616 
from 187 CKD patients and healthy kidney tissue sections of 96 additional individuals 617 
(Methods). We identified co-localization with the expression of 13 genes in at least one kidney 618 
tissue (Figure 6), the tissue with the strongest enrichment for urate-associated variants. 619 
Whereas co-localization of some genes was only observed in kidney (SLC17A4, BICC1, UMOD, 620 
 
 
19
GALNTL5, NCOA7), other genes showed co-localization across several tissues (e.g., ARL6IP5). 621 
The direction of change in gene expression with higher urate levels could vary for the same 622 
gene across tissues. For instance, the allele associated with higher serum urate at the SLC16A9 623 
locus was associated with higher gene expression in kidney, consistent with a regulatory variant 624 
in a transporter mediating the reabsorption of urate. The same allele was associated with lower 625 
gene expression in other tissues such as aorta, pointing towards tissue-specific regulatory 626 
mechanisms36. Details on each of the 13 genes with high posterior probability of a variant 627 
underlying the associations with both urate and gene expression in kidney are summarized in 628 
Supplementary Table 20. Significant co-localizations identified across all 47 tissues 629 
(Supplementary Figure 8) revealed additional novel insights such as co-localization of the urate 630 
association signal with NFAT5 expression in subcutaneous adipose tissue emphasizing its role in 631 
adipogenesis37, or PDZK1 expression in colon and ileum, important sites of urate excretion. 632 
Lastly, we investigated whether any trans-ethnic index SNPs or their proxies (r2>0.8) 633 
were reproducibly associated with gene expression in trans in whole blood or peripheral blood 634 
mononuclear cell in several large eQTL studies (Supplementary Table 21, Supplementary 635 
Information). We identified inter-chromosomal associations between five index SNPs and 16 636 
transcripts, that were enriched in the term “cardiovascular disease” based on the Human 637 
Disease Ontology database (Supplementary Information, Supplementary Table 22). 638 
 639 
HNF4A activates ABCG2 transcription and HNF4A p.Thr139Ile is a functional variant 640 
The gene and variant prioritization workflow was validated using the identified candidates 641 
HNF1A and HNF4A. Co-regulation of target genes by these master regulators of transcription in 642 
kidney proximal tubule cells and liver could potentially explain observed genetic correlations38. 643 
  We first tested whether HNF1A and HNF4A have the potential to affect transcription of 644 
the ABCG2 gene, which encodes for a urate transporter of major importance in humans and 645 
represented the locus with the highest risk for gout in our screen. ABCG2 contains several 646 
predicted HNF1A and HNF4A binding sites in its promoter region (Figure 5B). A luciferase 647 
reporter assay in the human embryonic kidney cell line HEK 293 was used to assess 648 
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transactivation of the human ABCG2 promoter by HNF4A and HNF1A proteins (Methods, 649 
Supplementary Figure 9A). Co-expression of HNF4A significantly increased the ABCG2 650 
promoter-driven luciferase activity, and the activation was dependent on the transfected 651 
HNF4A expression vector dose and corresponding levels of HNF4A protein (Figure 5C, 652 
Supplementary Figure 9B). As expected, no increase of luciferase activity occurred with the 653 
pGL4 vector without the ABCG2 promoter that was used as a negative control (Supplementary 654 
Figure 9D and 9E). Results for HNF1A indicated that the observed association of this locus with 655 
serum urate is unlikely to occur via activation of ABCG2 in kidney cells (Figure 5C), but HNF1A 656 
has been reported to activate transcription of PDZK1, a regulatory protein for several other 657 
renal urate transporters39,40  and also identified in this study. 658 
Next, we tested the functional relevance of the prioritized missense p.Thr139Ile allele in 659 
HNF4A (NM_178849.2, isoform 1, Methods). Its location within the hinge/ DNA binding domain 660 
(Figure 5D, Supplementary Figure 9F) supports potentially altered interactions with targeted 661 
promoter regions. The isoleucine to threonine substitution at position 139 significantly 662 
increased the transactivation of the ABCG2 promoter and commensurate luciferase activity as 663 
compared to the wild-type threonine (Figure 5E), without altering HNF4A protein abundance 664 
(Supplementary Figures 9C). Thus, HNF4A can activate ABCG2 transcription in a kidney cell line, 665 
and HNFA4 p.Thr139Ile is a functional variant. Increased activation of the urate excretory 666 
protein ABCG2 by the allele encoding the isoleucine residue should result in lower serum urate 667 
levels, consistent with the observed negative association in our GWAS.  668 
 669 
 670 
Discussion  671 
 672 
This large trans-ethnic GWAS meta-analysis of serum urate levels based on 457,690 individuals 673 
represents a four-fold increase in sample size over previous studies21,22,41 and resulted in the 674 
identification of 183 urate-associated loci, 147 of which are novel. A genetic urate risk score led 675 
to significant improvements of gout risk prediction among 334,880 independent persons, 3.5% 676 
of whom had a risk of gout comparable to a Mendelian disease effect size. Genetic correlation 677 
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and causality analyses confirmed the causal effect of urate on gout, and were consistent with 678 
transcriptional co-regulation as a source of pleiotropy in the widespread genetic correlations 679 
between serum urate and cardio-metabolic traits. Tissue and cell type-specific enrichment 680 
analyses supported kidney and liver, the sites of urate excretion and generation, as key target 681 
tissues. Comprehensive fine-mapping and co-localization analyses with gene expression across 682 
47 tissues delivered an extensive list of target genes and SNPs for follow-up studies, of which 683 
we experimentally confirmed HNF4A p.Thr139Ile as a functional allele involved in 684 
transcriptional regulation of urate homeostasis.  685 
Major challenges of GWAS are to pinpoint causal genes and variants, and to provide 686 
actionable insights into disease-relevant mechanisms and pathways in order to improve disease 687 
treatment and prevention. This study developed a comprehensive resource of candidate SNPs, 688 
genes, tissues and pathways involved in urate metabolism that will enable a wide range of 689 
follow-up studies such as our proof-of-principle validation study. Out of the many novel and 690 
biologically plausible findings, we highlight three instances in which co-localization of the serum 691 
urate and tissue-specific gene expression signals provides new insights into urate metabolism 692 
and the prominent role of the renal proximal tubules. First, co-localization helped to prioritize 693 
genes in association peaks that previous GWAS could not resolve. For example, the association 694 
signal at chromosome 6p22.2 contains the genes encoding four members of the SLC17 695 
transporter family (SLC17A1, SLC17A2, SLC17A3, and SLC17A4). Systematic testing of co-696 
localization across genes and tissues supported a variant underlying the urate association signal 697 
and differential gene expression only for SLC17A4 in kidney, with higher expression associated 698 
with higher serum urate. Previous experimental studies have implicated SLC17A4 as a urate 699 
exporter in intestine42, and our data support its yet unappreciated role in urate transport in the 700 
human kidney. Second, co-localization with gene expression provided insights into transport 701 
processes of the proximal tubule, the major site of urate reabsorption and excretion. For 702 
example, the gene product of the candidate ARL6IP5 has been shown to modulate activity of 703 
the glutamate transporter SLC1A143,44, dysfunction of which causes aminoaciduria45; and 704 
deletion of the candidate NCOA7 in mice results in distal renal tubular acidosis46. Third, it is 705 
noteworthy that co-localization of the urate association signal was observed with differential 706 
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expression of MUC1, BICC1 and UMOD in kidney. Rare mutations in all three genes are known 707 
to cause monogenic cystic kidney diseases47-49, pointing towards a shared mechanism with 708 
respect to their association with urate.  709 
Another noteworthy finding from this well-powered study was the significant genetic 710 
correlations with many cardio-metabolic traits, with directions matching expectation from 711 
known observational associations50. Many of these traits, like lipid levels and urate, are 712 
influenced by liver metabolism. We estimated the genetic causality proportion for these traits, 713 
showing that their genetic correlations are partly driven by overlapping or co-regulated 714 
metabolic pathways in the liver and not only by a fully causal effect of cholesterol or insulin 715 
levels on urate. Likewise, significant genetic correlations with kidney-related traits such as eGFR 716 
may reflect shared regulation of processes in the kidney, the major site of urate excretion. 717 
Evidence for transcriptional co-regulation, beyond the known importance of HNF1A and HNF4A 718 
in liver and kidney, is supported by the identification of additional urate loci such as MLXIPL, 719 
TCF7L2 and KLF10 that share associations with other metabolic and/or kidney function traits. 720 
The observed pleiotropic effects of many urate-associated variants could thus be the potential 721 
manifestation of co-regulation of processes that occur within and across tissues relevant to the 722 
implicated traits, a mechanism likely to be prevailing in metabolic, but also other traits.  723 
In the kidney, nuclear HNF4A is exclusively detected in epithelial cells of the proximal 724 
tubule51, where it has been reported to regulate the expression of SLC2A9 isoform 152 and 725 
PDZK153. Kidney-specific deletion of HNF4A in mice phenocopies Fanconi renotubular 726 
syndrome54. Detailed kidney tissues transcriptomic analyses support HNF4A to drive a proximal 727 
tubule signature cluster of 221 co-expressed genes, including many candidate genes for urate 728 
metabolism and transport51. In addition to HNF4A, HNF4G, and HNF1A, ten genes in this cluster 729 
of co-expressed genes also map into urate-associated loci identified here (A1CF, CUBN, LRP2, 730 
PDZK1, SERPINF2, SLC2A9, SLC16A9, SLC17A1, SLC22A12 and SLC47A1). In addition, our study 731 
establishes that HNF4A can also trans-activate transcription of ABCG2 in a kidney cell line, the 732 
key urate secretory transporter in both gut and kidney epithelium55. The T allele, encoding the 733 
isoleucine substitution at HNF4A T139I, showed higher trans-activation of ABCG2 transcription 734 
compared to the wild-type allele, which should result in increased urate secretion and is 735 
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consistent with the observed association of the T allele with lower serum urate levels. The 736 
genetic variant encoding the T139I substitution is located in a region of the HNF4A protein 737 
harboring many causative mutations for monogenic maturity onset diabetes of the young 738 
(MODY type 1)56. Yet, unlike the severe MODY1 missense mutations R127W, D126Y, and 739 
R125W,57 T139I has not been reported to cause MODY1. Instead, it has been reported to 740 
increase the risk of type 2 diabetes mellitus, possibly through a liver-specific loss of HNF4A 741 
phosphorylation at T139, and to associate with HDL-cholesterol levels56,58.  These data point to 742 
additional complexities when interpreting pleiotropic effects, because there may be several 743 
tissue-specific mechanisms by which genetic variants in transcriptional regulators influence 744 
metabolic pathways and urate homeostasis. 745 
Despite many strengths of this study, some limitations warrant mention. The numbers 746 
of individuals of ancestries other than European or East Asian were still small, highlighting the 747 
value of studying more diverse populations. Focusing on SNPs present in the majority of studies 748 
emphasizes those that may be of greatest importance globally over population-specific 749 
variants. General limitations of the field that are not specific to our study include the facts that 750 
statistical fine-mapping approaches based on summary statistics from meta-analyses cannot 751 
clearly prioritize functional variants in regions of tight LD, and that they are influenced by the 752 
availability of and imputation quality of SNPs in the individual contributing studies. Moreover, 753 
only few regulatory maps from important target tissues such as synovial membrane and kidney 754 
are available, but we were able to evaluate differential gene expression in three separate 755 
kidney datasets. The generation of additional regulatory and expression datasets across disease 756 
states, developmental stages and more cell types in the kidney and other metabolically active 757 
organs constitutes an important research avenue for the future.  758 
In summary, this large-scale genetic association study of serum urate generated an atlas 759 
of candidate SNPs, genes, tissues and pathways involved in urate metabolism and its shared 760 
regulation with multiple cardio-metabolic traits that will enable a wide range of follow-up 761 
studies. 762 
  763 
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 764 
Online Methods 765 
Overview of GWAS methods 766 
We developed an automated analysis workflow to collect and integrate results from 74 GWAS 767 
of serum urate from five ancestry groups participating in the CKDGen Consortium. We used a 768 
distributive model for study-specific GWAS with meta-analyses conducted centrally. An analysis 769 
plan was circulated to all participating studies accompanied by custom shell and R scripts for 770 
phenotype generation (https://github.com/genepi-freiburg/ckdgen-pheno). Study-specific 771 
GWAS were conducted after centralized review and approval of the phenotype summary 772 
statistics. Study-specific GWAS results were checked using GWAtoolbox59, including p-value 773 
inflation, allele frequency distribution, imputation quality, and completeness of genotypes. 774 
Custom scripts were used to compare imputed allele frequencies to those of ancestry-matched 775 
reference panels and to visualize variant positions. In addition, quality metrics, including the 776 
genomic control factor60, were compared across studies. The participants of all studies provided 777 
written informed consent. Each study had its research protocol approved by the corresponding 778 
local ethics committee. 779 
Phenotype definition, genotyping and imputation in participating studies 780 
The primary study outcome was serum urate in mg/dl. The laboratory methods for measuring 781 
serum urate in each study are reported in Supplementary Table 1. Prevalent gout was analyzed 782 
as a secondary outcome to examine whether urate-associated SNPs conferred gout risk. Gout 783 
cases were ascertained based on self-report, intake of urate-lowering medications, or 784 
International Statistical Classification of Diseases and Related Health Problems (ICD) codes for 785 
gout (Supplementary Table 1).  786 
 Each study performed genotyping separately and applied study-specific quality filters 787 
prior to phasing and imputation (Supplementary Table 2). In each study, haplotypes were 788 
estimated using MACH61, ShapeIT62, Eagle63, or Beagle64. Imputation of genotypes was 789 
conducted using reference panels from the Haplotype Reference Consortium (HRC) version 790 
1.165, 1000 Genomes Project (1000G) phase 3 v5 ALL, or the 1000G phase 1 v3 ALL66 and 791 
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ImputeV267, minimac368, PBWT69, the Sanger70, or the Michigan Imputation Server68. The 792 
imputed genetic dosages were annotated using NCBI b37 (hg19). Each study provided an 793 
imputation quality for each variant: ImputeV2 info score, the MACH/minimac RSQ or the 794 
SNPTest info score. 795 
Study-specific association analysis 796 
Each study performed ancestry-specific association analysis of serum urate by generating age- 797 
and sex-adjusted residuals of serum urate and regressing the residuals on SNP dosage levels, 798 
adjusting for study-specific covariates such as study centers and genetic principal components, 799 
assuming an additive genetic model. Gout was analyzed as a binary outcome adjusting for age, 800 
sex, genetic principal components, and study-specific covariates. Software used for these 801 
regression analyses were EPACTS (q.emmax for family based studies and q.linear otherwise; 802 
https://genome.sph.umich.edu/wiki/EPACTS), SNPTest71, RegScan72, RVTEST73, PLINK 1.9074, 803 
Probabel75, GWAF76, GEMMA77, mach2qtl78 and R. Family-based studies used methods that 804 
accounted for relatedness. 805 
Trans-ethnic, ancestry-specific, and sex-stratified meta-analyses 806 
GWAS results from each study were pre-filtered to retain bi-allelic SNPs with imputation quality 807 
score >0.6 and minor allele count (MAC) >10 before inclusion into meta-analysis. Fixed effects 808 
inverse-variance weighted meta-analysis was performed using METAL79 with modifications to 809 
output higher precision (six decimal places). Genomic control was applied for each study. The 810 
genomic inflation factor λGC60 was calculated to assess inflation of the test statistics. For each 811 
meta-analysis result (trans-ethnic, ancestry-specific, and sex-specific), we excluded SNPs that 812 
were present in <50% of the studies and with a total MAC <400. For ancestry-specific meta-813 
analysis, we additionally excluded SNPs with a heterogeneity I²-statistic80 >95%. Genome-wide 814 
significance was defined as p-value <5x10-8. The LD score regression intercept was calculated to 815 
assess the evidence for associations driven by population structure81. For downstream 816 
characterization, 8,249,849 and 8,217,339 autosomal SNPs were retained in the trans-ethnic 817 
and European ancestry meta-analysis, respectively. Ancestry-specific meta-analyses were 818 
conducted for European ancestry (EA), African Americans (AA), East Asian (EAS) ancestry, and 819 
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South Asian (SA) ancestry using the same methods and variant filters as the trans-ethnic meta-820 
analysis. 821 
Secondary meta-analyses were performed separately in men and women, using the 822 
same analytical approaches. To test for significant difference of association between males and 823 
females, we used a two-sample t-test 	ݐ = 	 ఉಾି	ఉಷ
ටௌாಾమା	ௌாಷమ
 824 
where ߚM and ߚF were beta coefficients in males and females, respectively, and SEM and 825 
SEF were the standard errors among males and females, respectively.  826 
 827 
Initial determination and annotation of genome-wide significant loci 828 
For each meta-analysis result, SNPs were assigned to loci by selecting the SNP with the lowest 829 
genome-wide p-value as the index SNP and defining the adjacent ±500kb-region as the 830 
corresponding locus. This procedure was repeated until no genome-wide significant SNP 831 
remained. An ancestry-specific locus was defined as a genome-wide significant locus in an 832 
ancestry-specific meta-analysis of which the index SNP did not map into within the ±500 kb 833 
intervals of any genome-wide significant loci in the trans-ethnic meta-analysis. Index SNPs were 834 
annotated using its position and the nearest gene based on hg19, RefSeq genes, and dbSNP147 835 
downloaded from ftp://hgdownload.soe.ucsc.edu/mysql/hg19/ on March 23rd, 2017. 836 
 837 
Proportion of phenotypic variance explained and estimated heritability 838 
The proportion of phenotypic variance explained by index SNPs was calculated as the sum of 839 
the variance explained by each index SNP based on this formula: ߚଶ ቀଶ௣ሺଵି௣ሻ௩௔௥ ቁ, where ߚ is the 840 
beta coefficient and ݌ is the MAF of the SNP, and ݒܽݎ is the phenotypic variance. For this study, 841 
we used the variance of the age- and sex-adjusted residuals of serum urate in EA participants of 842 
the ARIC study as the estimate of the phenotypic variance (variance=1.767).  843 
Heritability of age- and sex-adjusted urate was estimated using the R package 844 
‘MCMCglmm’82 in the Cooperative Health Research In South Tyrol (CHRIS) study,83 a 845 
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participating pedigree-based study of EA individuals, comprising 4,373 individuals in 186 846 
pedigrees of up to five generations. We estimated overall heritability, heritability excluding 847 
index SNPs in the three major urate loci (SLC2A9, ABCG2, and SLC22A12), and heritability 848 
excluding index SNPs in all genome-wide significant loci for both the trans-ethnic and EA-849 
specific meta-analyses. Estimates were obtained by running 1,000,000 MCMC iterations (burn 850 
in = 500,000) based on previously described settings84. The difference between the overall 851 
heritability and the heritability excluding the index SNPs represents the heritability explained by 852 
the significant loci in the present study. 853 
Trans-ethnic meta-regression  854 
Prior to conducting trans-ethnic meta-regression, we applied the same study-specific SNP filters 855 
as those applied to the fixed effects trans-ethnic meta-analysis (imputation quality score >0.6 856 
and MAC >10). An additional filter for MAF >0.0025 was also applied to reduce the influence of 857 
very rare SNPs that passed the MAC filter in very large studies. Trans-ethnic meta-regression 858 
was conducted using the MR-MEGA software package85, which models ancestry-associated 859 
heterogeneity in the allelic effect as a function of principal components (PCs) generated from a 860 
matrix of mean pairwise allele frequency differences between studies. Three principal 861 
components generated from a matrix of mean pairwise allele frequency differences between 862 
studies were sufficient to separate the self-reported ancestry groups. Due to software 863 
requirements, the minimum number of cohorts for each SNP had to be greater than the 864 
number of PCs plus two, resulting in the exclusion of SNPs present in five or fewer cohorts. The 865 
effect and p-value of each SNP on serum urate was reported, along with additional p-values 866 
per-SNP for ancestry-associated heterogeneity (panc-het) and residual heterogeneity (pres-het). 867 
Index SNPs from the fixed effects meta-analysis with panc-het <2.7x10-4 (0.05/183) in MR-MEGA 868 
were considered to have significant ancestry-associated heterogeneity.  869 
Effect of urate-associated index SNPs on gout and risk prediction for gout 870 
 
 
28
To evaluate the association of the trans-ethnic urate-associated index SNPs with gout, we 871 
conducted a trans-ethnic meta-analysis of gout with the same study-specific filtering criteria as 872 
for the urate trans-ethnic meta-analysis.  873 
 The association between a genetic urate risk score constructed from the 114 874 
independent serum urate-associated SNPs identified among European individuals (see fine-875 
mapping section below) and gout was assessed in a large, independent sample from the UKBB 876 
(Projects 19655 and 20272)86. We selected 334,880 unrelated individuals (pairwise kinship 877 
coefficient<0.0313) of White British ancestry with sex chromosome euploidy and concordance 878 
of phenotypic and genotypic sex, including 4,908 with gout identified by self-report at the 879 
inclusion visit. Individuals with an ICD10 for gout  (M10) in hospital admissions who did not self-880 
report gout were excluded from the analysis. A genetic risk score (GRS) was constructed as the 881 
sum of the imputed dosage of the allele associated with higher urate levels (“risk alleles”) over 882 
all SNPs, multiplied by the genetic effect of the risk allele on serum urate levels. The GRS 883 
distribution was divided into ten evenly-spaced categories, and individuals assigned to a 884 
category based on their GRS. The category with the lowest GRS did not contain any gout cases 885 
and so was combined with its adjacent category. Gout status was regressed on GRS category in 886 
a logistic model, including age and sex as covariates, with the category containing the largest 887 
number of individuals (genetically predicted mean urate levels 4.74-5.02 mg/dl higher 888 
compared to individuals without any urate-increasing alleles) as the reference group. 889 
The performance of the GRS for risk prediction of gout was trained on a set containing 890 
90% of the sample and tested on the remaining 10%. Logistic regression was used to regress 891 
gout on the GRS alone (genetic model), age and sex (demographic model) and GRS with age and 892 
sex (combined model). Each of these models was then used to predict gout status in the test 893 
set.  Model performance was assessed by comparing predicted and true gout status using Area 894 
Under the Curve (AUC) in a Receiver Operating Characteristic (ROC) curve. An optimum cutoff 895 
of the ROC curve to report sensitivity and specificity of a combined GRS-based diagnostic test 896 
was determined by the maximum of the Youden's index (sensitivity+specificity-1).  897 
 898 
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Genetic correlation 899 
To assess the genetic correlation between serum urate and other traits in EA, we conducted 900 
cross-trait LD score regression87 using LD Hub88 with the EA-specific urate meta-analysis results 901 
as input. Genetic correlation estimates with 746 traits were obtained from LD Hub, excluding 902 
two previous serum urate GWAS results. For presentation, the 212 significantly correlated traits 903 
(p<6.7x10-5=0.05/746) were grouped into 9 categories based on the trait names and labels and 904 
presented in a circos plot. 905 
 To determine whether observed genetic correlations between serum urate and cardio-906 
metabolic traits are likely to represent causal relationships, we used the recently-developed 907 
latent causal variable (LCV) method to estimate the genetic causality proportion (GCP) between 908 
serum urate and another trait.89 The GCP describes what proportion of the genetic component 909 
of one trait also affects the other trait; a positive GCP value indicates that a large proportion of 910 
the genetic component of urate also affects the other trait, and vice versa for a negative GCP 911 
value. LCV produces posterior mean and standard deviation estimates of the GCP using mixed 912 
fourth moments of the bivariate effect size distribution, based on GWAS summary statistics and 913 
LD scores. When using summary statistics of cardio-metabolic traits generated from the UKBB, 914 
we assumed non-overlapping populations, and overlapping populations otherwise. We selected 915 
six unique continuous cardio-metabolic traits commonly examined in epidemiological studies 916 
with high genetic correlation with serum urate (|rg|>0.35). We additionally included gout as a 917 
positive control and creatinine-based glomerular filtration rate. EA-specific GWAS summary 918 
statistics were used as input to match the ancestry of the LD scores used with the method 919 
(https://data.broadinstitute.org/alkesgroup/LDSCORE/eur_w_ld_chr.tar.bz2).    920 
Functional enrichment 921 
To assess gene-set and tissue enrichment, we used the Data-Driven Expression Prioritized 922 
Integration for Complex Traits analysis (DEPICT) version 1 release 19490. DEPICT performs gene 923 
set enrichment analysis by testing whether genes in 14,461 reconstituted gene sets were 924 
enriched for urate-associated SNPs. These reconstituted gene sets were generated based on 925 
similarity analysis from gene expression of 77,840 samples, manually curated gene-sets, 926 
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molecular pathways from protein-protein interaction screening, and gene sets from mouse 927 
gene knock-out studies. Additionally, gene expression levels of from 37,427 human microarray 928 
samples are compiled in DEPICT and the tissue and cell types were mapped to 209 MeSH first 929 
level terms including physiological systems, tissues and cells. Enrichment of tissues and cell 930 
types was conducted by assessing whether urate-associated genes are highly expressed in the 931 
tissue and cell types.  932 
All variants with urate association p-values <1x10-5 from the trans-ethnic meta-analysis 933 
results were used as input. Independent SNPs were identified using PLINK 1.974 clump 934 
command within 500 kb flanking regions and r²>0.1 in the 1000 Genomes phase1 version 3 data 935 
excluding the MHC region (chr6:25–35 Mb). False discovery rates (FDRs) were computed using 936 
500 repetitions, and p-values were computed using 5,000 permutations from 500 null GWAS 937 
sets adjusting for gene length.  938 
 Affinity propagation clustering (APC)91, implemented in the R package ‘APCluster’92, was 939 
applied to all reconstituted gene sets with FDR-corrected enrichment P-value <0.01 to cluster 940 
gene sets containing similar combinations of genes. Similarity between sets was assessed by the 941 
z-scores of the top ten genes assigned to each gene set. The algorithm identifies a single 942 
reconstituted gene set from each cluster as an exemplar (meta gene set) that best represents 943 
the reconstituted gene sets within that cluster. A correlation matrix was calculated from the Z-944 
scores of the top ten genes within the meta gene set. Correlations >0.2 were visualized as 945 
edges in a network in Cytoscape (http://cytoscape.org). 946 
Stratified LD score regression for functional enrichment 947 
Stratified LD score regression87 estimates the SNP heritability of urate contributed by the SNPs 948 
linked to histone marks in each cell type. The enrichment of a category is defined as the 949 
proportion of SNP heritability in that cell type divided by the proportion of SNPs in the same cell 950 
type. Here, we assessed urate heritability enrichment in 10 cell types via stratified LD score 951 
regression with the EA-specific urate meta-analysis results as the input to match the ancestry of 952 
the LD score estimates. The 10 cell types were collapsed from 220 cell type-specific annotations 953 
for four histone marks: H3K4me1, H3K4me3, H3K9ac, and H3K27ac. Analyses were also carried 954 
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out using trans-ethnic meta-analysis summary statistics as input and results were similar (data 955 
not shown).  956 
Statistical fine-mapping of genome-wide significant loci in European ancestry 957 
Statistical fine-mapping to identify potentially causal variants was performed for the genome-958 
wide significant loci from the EA-specific meta-analysis, because fine-mapping based on 959 
summary statistics relies on LD estimates from an ancestry-matched reference panel whose 960 
sample size should scale with that of the GWAS (Methods)34. We estimated LD from genotypes 961 
of 15,000 randomly selected UKBB participants (Application ID 2027, Dataset ID 8974). First, we 962 
removed individuals who withdrew consent, those with mismatched sex between self-reported 963 
and genetic, with genotype call rates <95%, outliers of variant heterozygosity or along the first 964 
two principal components from a principal component analysis seeded with the HapMap phase 965 
3 release 2 populations. We retained only one member of each pair of individuals with pair-966 
wise identity-by-descent statistic ≥0.1875. Altogether, 13,558 individuals with 16,969,363 SNPs 967 
were selected as the LD reference panel for fine-mapping. 968 
  Statistical fine-mapping was conducted by first combining neighboring loci with 969 
correlated index SNPs (r2≥0.2) in the EA meta-analysis into discrete regions. Next, we 970 
performed stepwise model selection using GCTA (cojo-slct option) to identify independent 971 
index SNPs in each region. For regions with more than one independent index SNPs, we 972 
performed conditional analysis (GCTA cojo-cond option) to obtain conditional beta and 973 
standard errors. Approximate Bayes factors (ABF) were calculated using the Wakefield’s 974 
formula35, as implemented in the R package ’gtx’ version 2.0.1 975 
(https://github.com/tobyjohnson/gtx) using the conditional betas and standard errors for 976 
regions with multiple independent SNPs and the betas and standard errors of the original EA 977 
meta-analysis for regions with a single independent index SNP. The prior standard deviation 978 
was calculated as 0.061 based on formula (8) of the original publication of the Wakefield’s 979 
formula (ref) and the 95% interval of the SNP effect sizes in the EA meta-analysis. The posterior 980 
probability for a variant being the driver of the association signal was calculated as the ABF of 981 
the variant divided by the sum of the ABF in the region. The 99% credible sets of a region is 982 
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derived by summing the posterior probabilities in descending order until the cumulative 983 
posterior probability was >99%.  984 
Annotation of the variants in the credible sets 985 
We annotated SNPs in the credible sets for their exonic effect, Combined Annotation 986 
Dependent Depletion (CADD) score, and mapping into DNaseI-hypersensitive sites (DHS) from 987 
the Encyclopedia of DNA Elements (ENCODE) and Roadmap Epigenomics Consortium 988 
projects93,94. The exonic effect and CADD score were obtained using SNiPA v3.2 (March 2017)95. 989 
SNiPA presented the CADD score as PHRED-like transformation of the C score, which was based 990 
on CADD release v1.3 downloaded from http://cadd.gs.washington.edu/download. A CADD 991 
score of 15 is used to distinguish potential pathogenic variants from background noise in clinical 992 
genetics, and represents the median value of all non-synonymous variants in CADD v1.096,97. 993 
Co-localization analysis of cis-eQTL and urate-associated loci 994 
Co-localization analysis of urate-associated loci with gene expression was conducted using EA-995 
specific urate meta-analysis results, cis-eQTL results from micro-dissected human glomerular 996 
and tubulo-interstitial kidney portions from 187 individuals in the NEPTUNE study98, as well as 997 
from 44 tissues in the GTEx Project version 6p release99. For each locus, we identified all 998 
transcripts and all tissue-transcript pairs with reported eQTLs within ±100 kb of each GWAS 999 
index SNP. The region for each co-localization test was defined as the eQTL cis window in the 1000 
underlying studies98,99. We used the default parameters and prior definitions set in the 1001 
‘coloc.fast’ function from the R package ‘gtx’ (https://github.com/tobyjohnson/gtx), which is an 1002 
adapted implementation of Giambartolomei’s colocalization method24. Evidence for co-1003 
localization was defined as H4 ≥0.8, which represents the posterior probability that the 1004 
association with serum urate and gene expression is due to the same underlying variant. In 1005 
addition, co-localization of urate-associated loci was also performed with gene expression 1006 
quantified using RNA sequencing of the healthy tissue portion of 99 kidney cortex samples from 1007 
the Cancer Genome Atlas (TCGA)100. First, all transcripts that shared eQTL variants with urate 1008 
index SNPs within ±100 kb were extracted. Then the posterior probability of co-localization was 1009 
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calculated including eQTLs within the cis-window (±1Mb from the transcription start site) for 1010 
each gene using the R coloc package24 with default values for the three prior probabilities. 1011 
Trans-eQTL annotation  1012 
We performed trans-eQTL annotation for the 183 trans-ethnic index SNPs and their proxies (r2 1013 
>0.8 in both the 1000 Genomes phase 3 European and East Asian reference panels) in eQTL 1014 
studies with >1,000 individuals: the Framingham Heart Study101, Westra et al.102, Zeller et al.103, 1015 
Fehrmann et al.104, and the LIFE Heart105 and LIFE-Adult106 studies (details in Supplementary 1016 
Methods). To improve stringency of results, we only report inter-chromosomal trans-eQTLs 1017 
showing gene expression association p-values <5x10-8 in at least two of the above mentioned 1018 
independent samples. To characterize whether the identified trans-associated eQTL transcripts 1019 
were enriched in any biological pathways, we conducted gene enrichment analysis using DOSE, 1020 
an R/Bioconductor package for disease ontology semantic and enrichment analysis107, as well as 1021 
packages ReactomePA and clusterProfiler for enrichment analysis using the Human Disease 1022 
Ontology database, GO, KEGG, and Reactome.108-112 The background included all 19,327 1023 
protein-coding genes from Ensembl/Havana reported in Ensembl release 91. 1024 
 1025 
Experimental study 1026 
Promoter Binding Site Predictions 1027 
For promoter binding site predictions, we used the JASPAR 2018 database113,114. The frequency 1028 
matrices were downloaded for transcription factor binding sites of both vertebrate and human 1029 
sequences (HNF1A: MA0046.1 and MA0046.2; HNF4A: MA0114.1 and MA0114.2). These 1030 
matrices were then used to query the promoter region of ABCG2 (-1285/+362, or base pairs 1031 
upstream of the transcription start site / and downstream after transcription start site)115 by 1032 
means of the LASAGNA 2.0 transcription factor binding site search tool with default parameters 1033 
and a p-value cutoff of 0.01116.  1034 
Site-Directed Mutagenesis 1035 
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HNF1A and HNF4A clones were purchased from GeneCopoeia, (EX-A7792-M02 and EX-Z5283-1036 
M02 respectively) and were mutagenized using the QuikChange Lightning Site Directed 1037 
Mutagenesis kit (Agilent Technologies, #210518) per manufacturer’s instructions using PAGE 1038 
purified primers.  1039 
HNF1A-A98V-Forward: CCCTGAGGAGGCGGTCCACCAGAAAGCCG;  1040 
HNF1A-A98V-Reverse: CGGCTTTCTGGTGGACCGCCTCCTCAGGG;  1041 
HNF4A-T139I-Forward: GACCGGATCAGCATTCGAAGGTCAAGC;  1042 
HNF4A-T139I-Reverse: GCTTGACCTTCGAATGCTGATCCGGTC. 1043 
Luciferase Assay 1044 
HEK293T cells were seeded in white-walled 96-well plates coated with Poly-L-lysine at roughly 1045 
12,500 cells per well. Cells were transfected 18 hours later with either the ABCG2 promoter (-1046 
1285/+362) upstream of a firefly luciferase in the pGL4.14 vector (a generous gift from Douglas 1047 
D. Ross, University of Maryland School of Medicine), or the pGL4.14 vector (Promega, #E699A) 1048 
without promoter construct, as well as GFP expressing vector used as an internal negative 1049 
control (pEGFP-C1, Clontech)117 using X-tremeGeneTM 9 DNA Transfection Reagent (Roche 1050 
Diagnostics, #6365787001). Transfection cocktails were prepared per manufacturer’s 1051 
specifications either with or without transcription factor using the following ratio: 0.6 μg 1052 
promoter construct, 0.2, 0.1, or 0.05 μg transcription factor, and 0.05 μg GFP. When no 1053 
transcription factor was used, pcDNA3.1 was substituted. Approximately 48 hours after 1054 
transfection, cells were rinsed with 1x PBS, then lysed using Passive Lysis Buffer (Promega 1055 
#E194A) for 15 minutes. During this incubation, GFP measurements were taken using a 1056 
CLARIOstar microplate reader (BMG Labtech). Next, 30 μl of Luciferase Reagent (Promega, 1057 
E297A&B) were added to each well, and the plate was incubated for an additional 20 minutes 1058 
at room temperature. Finally, luciferase activity was measured using the CLARIOstar microplate 1059 
reader taking the average over 6 seconds. To evaluate the significance of transactivation of the 1060 
ABCG2 promoter we compared cells expressing transcription factors to those transfected with 1061 
the empty vector (pcDAN3.1) and to evaluate TF dose responses or differences in TF variants all 1062 
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experimental conditions from one plate were compared using an Ordinary one-way ANOVA, 1063 
accounting for multiple comparisons with a Tukey’s multiple comparison test. Statistical 1064 
analysis was performed using Prism 7 (GraphPad Software Inc, USA). 1065 
Western Blots 1066 
Equal volumes of deoxycholate-RIPA buffer were added to wells containing desired lysates 1067 
following the luciferase assay and plates were then incubated at 4°C overnight. Equal volumes 1068 
of sample + 5x SDS loading dye + 10% ߚ-merceptoethanol were then loaded into 10% Mini-1069 
PROTEAN® TGX Stain-Free™ Precast Gels (Bio-Rad, #4568033) and run per manufacturer’s 1070 
specifications. Gels were then cross-linked for 45 seconds and imaged to reveal total protein 1071 
load, which was used as the loading control for each lane (representative images of these 1072 
protein gels are found in S.upplementary figure 9). Gels were then transferred onto 1073 
nitrocellulose membranes using the Trans-Blot® Turbo™ Transfer System (Bio-Rad), blocked for 1074 
2 hours at room temperature in 5% milk in TBS-T, and  incubated overnight at 4°C with primary 1075 
antibody. Membranes were then washed 3 times with TBS-T, incubated at room temperature 1076 
for 1 hour  with Donkey anti-rabbit secondary antibody (Jackson ImmunoResearch, #111-035-1077 
144) diluted 1:5000 in 2.5% milk in TBS-T. Membranes were then washed again and developed 1078 
using SuperSignal™ West Pico PLUS Chemiluminescent Substrate (Thermo Scientific, #34577) 1079 
and imaged on the ChemiDoc MP imaging system (Bio-Rad). All primary antibodies were diluted 1080 
1:1000 in 2.5% milk in TBS-T. Antibodies used included HNF4α (Cell Signaling Technology, 1081 
#3113) and HNF1α (Cell Signaling Technology, #89670). Antibodies were validated using lysates 1082 
of overexpressing HEK293T cells transfected with either HNF construct, demonstrating bands at 1083 
the appropriate sizes (Supplementary Figure 9). 1084 
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Table 1: Genes implicated as causal via identification of missense variants with high probability of driving the urate association 1085 
signal. Genes are included if they contain a missense variant with posterior probability of association of >50% or mapping into a 1086 
small credible set (≤5 variants). 1087 
Gene SNP #SNPs 
in set  
SNP 
PP 
consequence CADD DHS Gout p-
value (EA) 
Brief summary of literature and gene function
ABCG2 rs2231142 4 0.41 p.Gln141Lys
(NP_004818.2) 
18.2 ENCODE 
epithelial 
1.21E-290 Encodes a xenobiotic and high-capacity urate membrane transporter expressed in kidney, liver 
and gut. Causal variants have been reported for gout susceptibility (#138900) and the Junior 
Jr(a-) blood group phenotype (#614490). The locus was first identified in association with serum 
urate through GWAS (PMID:18834626) and confirmed in many studies since. The common 
causal variant Q141K has been experimentally confirmed (PMID:19506252) as a partial loss of 
function.  
UNC5C
L 
rs742493 4 0.95 p.Arg432Gly 
(NP_775832.2) 
 
(within Death 
domain) 
21.0 ENCODE 
epithelial 
2.73E-01 Encodes for the death-domain-containing Unc-5 Family C-Terminal-Like membrane-bound 
protein. Suggested as a candidate gene for mucosal diseases, with a role in epithelial 
inflammation and immunity (PMID:22158417). Experiments using human HEK293 cells showed 
that UNC5CL can transduce pro-inflammatory programs via activation of NF-B, with the 432Gly 
variant less potent to do so than the 432Arg one (PMID:22158417). 
HNF1A rs1800574 2 0.92 p.Ala98Val 
(NP_000536.5) 
23.4 1.83E-02 Encodes a transcription factor with strong expression in liver, guts and kidney. Rare mutations 
cause autosomal-dominant MODY type III (#600496). Locus found in GWAS of T2DM 
(PMID:22325160) and blood urea nitrogen (PMID:29403010). Together with HNF4-alpha, it was 
first recognized as master regulator of hepatocyte and islet transcription. Knockout mice show 
proximal tubular dysfunction (Fanconi syndrome). HNF1A enhanced promoter activity of PDZK1, 
URAT1, NPT4 and OAT4 in human renal proximal tubule cell-based assays (PMID:28724612), 
supporting a role in the coordinated expression of components of the urate “transportosome”.  
HNF4A rs1800961 1 1.00 p.Thr139Ile 
(NP_000448.3) 
24.7 ENCODE 
pancreas 
7.43E-03 Encodes another nuclear receptor and transcription factor that controls expression of many 
genes, including HNF1A and other overlapping target genes. Rare mutations cause autosomal-
dominant MODY type I (#125850) and autosomal-dominant renal Fanconi syndrome 4 (# 
616026). Shown to regulate expression of SLC2A9 and other members of the urate 
"transportosome" in cell-based assays (PMID 25209865, PMID:30124855). The GWAS locus has 
been reported for multiple cardio-metabolic traits and T2DM (PMID:21874001). 
CPS1 rs1047891 84 0.84 p.Thr1412Asn 
(NP_001116105.1) 
22.1 5.66E-02 Encodes mitochondrial carbamoyl phosphate synthetase I, which catalyzes the first committed 
step of the urea cycle by synthesizing carbamoyl phosphate from ammonia, bicarbonate, and 2 
molecules of ATP. Rare mutations cause autosomal-recessive carbamoylphosphate synthetase I 
deficiency (#237300). In addition to hyperammonemia, this disease features increased synthesis 
of glutamine, a precursor of purines. Elevated uric acid excretion has been reported in patients 
with hyperammonemia (PMID:6771064). GWAS locus for eGFR (PMID:26831199), homocysteine 
(PMID:23824729), urinary glycine concentrations (PMID: 26352407). 
GCKR rs1260326 2 0.67 p.Leu446Pro 
(NP_001477.2) 
0.1 ENCODE 
kidney 
4.09E-41 Encodes a regulatory protein prominently expressed in the liver that inhibits glucokinase. 
Identified in previous GWAS of urate (PMID:23263486) and multiple other cardio-metabolic 
traits. The 446L protein was shown to be less activated than 446Pro by physiological 
concentrations of fructose-6-phosphate, leading to reduced glucokinase inhibitory ability 
(PMID:19643913). 
Abbreviation: PP, posterior probability; DHS, DNase-I hypersensitivity site; CADD, Combined Annotation Dependent Depletion phred score; EA, European ancestry.1088 
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Figure Legends 1242 
Figure 1: Trans-ethnic GWAS meta-analysis identifies 183 loci associated with serum urate 1243 
Outer ring: Dot size represents the genetic effect size of the index SNP at each labeled locus on 1244 
serum urate. Blue band: –log10(p) for association with serum urate, by chromosomal position 1245 
(GRCh37 (hg19) reference build). Red line indicates genome-wide significance (p=5×10-8). Blue 1246 
gene labels indicate novel loci, gray labels loci reported in previous GWAS of serum urate. 1247 
Green band: –log10(p) for association with gout, by chromosomal position. Red line indicates 1248 
genome-wide significance (p=5×10-8). Inner band: Dots represent index SNPs with significant 1249 
heterogeneity and are color-coded according to its source: green for ancestry-related 1250 
heterogeneity (panc-het <2.7×10-4 [0.05/183]), red for residual heterogeneity (pres-het <2.7×10-4), 1251 
and yellow for both (panc-het and pres-het <2.7×10-4). Loci are labeled with the gene closest to the 1252 
index SNP. 1253 
 1254 
Figure 2: A genetic risk score (GRS) for serum urate improves gout risk prediction. (A) 1255 
Histogram of the urate GRS among 334,880 European ancestry participants of the UK Biobank. 1256 
The Y axes show the number of individuals (left) and the prevalence of gout (right), the x-axis 1257 
shows categories of the urate GRS. The units on the x-axis represent genetically-predicted 1258 
serum urate levels (mg/dl) compared to individuals without any urate-increasing alleles; (B) Y 1259 
axis displays the age- and sex-adjusted odds ratio of gout by GRS category (X axis), comparing 1260 
each other category to the most prevalent one; (C) Comparison of the receiver operating 1261 
characteristic (ROC) curves of different prediction models of gout: genetic (GRS only; red), 1262 
demographic (age + sex; green), and combined (GRS + age + sex; blue). Y-axis: sensitivity, x-axis: 1263 
specificity. At the optimal cut points determined by the maximum of the Youden’s index, the 1264 
sensitivity of the combined model was 84% and specificity was 68%.  1265 
 1266 
Figure 3: Serum urate shows widespread genetic correlations with cardio-metabolic risk 1267 
factors and diseases. 1268 
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The Circos plot shows significant genome-wide genetic correlations between serum urate and 1269 
214 complex traits or diseases (p<6.6x10-5), with bar height proportional to the genetic 1270 
correlation coefficient (rg) estimate for each trait and coloring according to its direction (dark 1271 
blue, rg>0; light blue, rg<0). Traits and diseases are labeled on the outside of the plot and 1272 
grouped into nine different categories. Each category is color-coded (inner ring, inset). The 1273 
greatest genetic correlation was observed with gout (rg=0.92, p=3.3x10-70). Genetic correlations 1274 
with multiple cardio-metabolic risk factors and diseases reflect their known directions from 1275 
observational studies. 1276 
 1277 
Figure 4: Genes expressed in urate-associated loci are enriched in kidney tissue and 1278 
pathways. (A) Grouped physiological systems (x-axis) that were tested individually for 1279 
enrichment of expression of genes in urate-associated loci are shown as a bar plot, with the –1280 
log10(P-value) on the y-axis. Significantly enriched systems are labeled and highlighted in blue 1281 
(false discovery rate [FDR] <0.01). (B) Correlated (r > 0.2) meta-gene sets that were strongly 1282 
enriched for genes mapping into urate-associated loci (FDR <0.01). Thickness of the edges 1283 
represents the magnitude of the correlation coefficient, node size, color and intensity represent 1284 
the number of clustered gene sets, gene set origin, and enrichment p-value, respectively. 1285 
 1286 
Figure 5: Prioritization of p.Thr139Ile at HNF4A and functional study of HNF4A regulation of 1287 
ABCG2 transcription. 1288 
(A) Graph shows credible set size (x-axis) against the posterior probability of association (PPA; 1289 
y-axis) for each of 1,453 SNPs with PPA >1% in 114 99% credible sets. Triangles mark missense 1290 
SNPs, with size proportional to their Combined Annotation Dependent Depletion (CADD) score. 1291 
Blue triangles indicate missense variants mapping into small (≤5 SNPs) credible sets or with high 1292 
PPA (≥50%). (B) Predicted HNF1A or HNF4A binding sites in the promoter region of ABCG2, the 1293 
consensus affinity sequence, and the p-value of likely matches. (C) Relative luciferase activity 1294 
and transactivation of ABCG2 promoter in cells transfected with variable amount of HNF1A or 1295 
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HNF4A constructs. ± SEM, n=3 independent experiments, p values calculated with ordinary one-1296 
way ANOVA with Tukey’s multiple comparison test. (D) Position of p.Thr139Ile (T139I) in DNA 1297 
binding domain / hinge region within HNF4A homodimer structure (PDB 4IQR). (E) Relative 1298 
luciferase activity and transactivation of ABCG2 promoter in cells transfected with variable 1299 
amount of constructs (ng’s of transfected DNA) of wild-type HNF4A (threonine) or isoleucine at 1300 
position 139. ± SEM, n=3 independent experiments, p values calculated with ordinary one-way 1301 
ANOVA with Tukey’s multiple comparison test. 1302 
 1303 
Figure 6: Co-localization of urate-association signals with gene expression in cis in kidney 1304 
tissues 1305 
Serum urate association signals identified among European ancestry individuals were tested for 1306 
co-localization with all eQTLs where the eQTL cis-window overlapped (±100 kb) the index SNP. 1307 
Genes with ≥1 positive co-localization (posterior probability of one common causal variant, H4, 1308 
≥0.80) in a kidney tissue are illustrated with the respective index SNP and transcript (y-axis). Co-1309 
localizations across all tissues (x-axis) are illustrated as dots, where the size of the dots indicates 1310 
the posterior probability of the co-localization. Negative co-localizations (posterior probability 1311 
of H4 <0.80) are marked in gray, while the positive co-localizations are color-coded based on 1312 
the predicted change in expression relative to the allele associated with higher serum urate. 1313 
 1314 
Table 1: Genes implicated as causal via identification of missense variants with high 1315 
probability of driving the urate association signal. Genes are included if they contain a 1316 
missense variant with posterior probability of association of >50% or mapping into a small 1317 
credible set (≤5 variants). 1318 
  1319 
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Table 1: Genes implicated as causal via identification of missense variants with high probability of driving the urate 
association signal. Genes are included if they contain a missense variant with posterior probability of association of >50% or 
mapping into a small credible set (≤5 variants). 
Gene SNP #SNPs 
in set  
SNP 
PP 
consequence CADD DHS Gout p-
value (EA) 
Brief summary of literature and gene function
ABCG2 rs2231142 4 0.41 p.Gln141Lys
(NP_004818.2) 
18.2 ENCODE 
epithelial 
1.21E-290 Encodes a xenobiotic and high-capacity urate membrane transporter expressed in kidney, liver 
and gut. Causal variants have been reported for gout susceptibility (#138900) and the Junior 
Jr(a-) blood group phenotype (#614490). The locus was first identified in association with serum 
urate through GWAS (PMID:18834626) and confirmed in many studies since. The common 
causal variant Q141K has been experimentally confirmed (PMID:19506252) as a partial loss of 
function.  
UNC5C
L 
rs742493 4 0.95 p.Arg432Gly 
(NP_775832.2) 
 
(within Death 
domain) 
21.0 ENCODE 
epithelial 
2.73E-01 Encodes for the death-domain-containing Unc-5 Family C-Terminal-Like membrane-bound 
protein. Suggested as a candidate gene for mucosal diseases, with a role in epithelial 
inflammation and immunity (PMID:22158417). Experiments using human HEK293 cells showed 
that UNC5CL can transduce pro-inflammatory programs via activation of NF-B, with the 432Gly 
variant less potent to do so than the 432Arg one (PMID:22158417). 
HNF1A rs1800574 2 0.92 p.Ala98Val 
(NP_000536.5) 
23.4 1.83E-02 Encodes a transcription factor with strong expression in liver, guts and kidney. Rare mutations 
cause autosomal-dominant MODY type III (#600496). Locus found in GWAS of T2DM 
(PMID:22325160) and blood urea nitrogen (PMID:29403010). Together with HNF4-alpha, it was 
first recognized as master regulator of hepatocyte and islet transcription. Knockout mice show 
proximal tubular dysfunction (Fanconi syndrome). HNF1A enhanced promoter activity of PDZK1, 
URAT1, NPT4 and OAT4 in human renal proximal tubule cell-based assays (PMID:28724612), 
supporting a role in the coordinated expression of components of the urate “transportosome”.  
HNF4A rs1800961 1 1.00 p.Thr139Ile 
(NP_000448.3) 
24.7 ENCODE 
pancreas 
7.43E-03 Encodes another nuclear receptor and transcription factor that controls expression of many 
genes, including HNF1A and other overlapping target genes. Rare mutations cause autosomal-
dominant MODY type I (#125850) and autosomal-dominant renal Fanconi syndrome 4 (# 
616026). Shown to regulate expression of SLC2A9 and other members of the urate 
"transportosome" in cell-based assays (PMID 25209865, PMID:30124855). The GWAS locus has 
been reported for multiple cardio-metabolic traits and T2DM (PMID:21874001). 
CPS1 rs1047891 84 0.84 p.Thr1412Asn 
(NP_001116105.1) 
22.1 5.66E-02 Encodes mitochondrial carbamoyl phosphate synthetase I, which catalyzes the first committed 
step of the urea cycle by synthesizing carbamoyl phosphate from ammonia, bicarbonate, and 2 
molecules of ATP. Rare mutations cause autosomal-recessive carbamoylphosphate synthetase I 
deficiency (#237300). In addition to hyperammonemia, this disease features increased synthesis 
of glutamine, a precursor of purines. Elevated uric acid excretion has been reported in patients 
with hyperammonemia (PMID:6771064). GWAS locus for eGFR (PMID:26831199), homocysteine 
(PMID:23824729), urinary glycine concentrations (PMID: 26352407). 
GCKR rs1260326 2 0.67 p.Leu446Pro 
(NP_001477.2) 
0.1 ENCODE 
kidney 
4.09E-41 Encodes a regulatory protein prominently expressed in the liver that inhibits glucokinase. 
Identified in previous GWAS of urate (PMID:23263486) and multiple other cardio-metabolic 
traits. The 446L protein was shown to be less activated than 446Pro by physiological 
concentrations of fructose-6-phosphate, leading to reduced glucokinase inhibitory ability 
(PMID:19643913). 
Abbreviation: PP, posterior probability; DHS, DNase-I hypersensitivity site; CADD, Combined Annotation Dependent Depletion phred score; EA, European ancestry.
 
